TSEN34

Across TCGA pan-cancer cohorts, TSEN34 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TSEN34 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TSEN34 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TSEN34 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where TSEN34 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.316	0.838	.002	35	view →
LUAD	DFS	Median	II,III,IV	0.986	0.720	.001	20	view →
GBM	OS	Median	All	0.473	0.288	.022	6	view →
HNSC	OS	Tertile	III,IV	0.498	1.000	.049	2	view →
CCRCC	OS	Median	III,IV	0.842	1.000	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TSEN34–PDAC (OS)

Open the PDAC breakdown →